Literature DB >> 23842103

Pentraxin 3 and other inflammatory factors in central retinal vein occlusion and macular edema.

Hidetaka Noma1, Tatsuya Mimura, Hidetaka Masahara, Katsunori Shimada.   

Abstract

PURPOSE: To evaluate the association between vitreous fluid levels of inflammatory factors and macular edema in patients with central retinal vein occlusion (CRVO).
METHODS: In 30 CRVO patients with macular edema and 29 controls with idiopathic macular hole, vitreous fluid samples were obtained during vitreoretinal surgery. Retinal ischemia was evaluated from capillary nonperfusion on fluorescein angiography. Macular edema was examined by optical coherence tomography.
RESULTS: Vitreous fluid levels of vascular endothelial growth factor (VEGF), soluble VEGF receptor 2 (sVEGFR-2), soluble intercellular adhesion molecule 1 (sICAM-1), interleukin 6 (IL-6), monocyte chemotactic protein 1 (MCP-1), and pentraxin 3 (PTX3) were significantly higher in CRVO patients than in macular hole patients. Vitreous fluid levels of VEGF, sICAM-1, IL-6, MCP-1, and PTX3 were significantly correlated with the retinal thickness at the central fovea. There were significant correlations between the vitreous fluid level of VEGF and the levels of sICAM-1, IL-6, and MCP-1 in the CRVO patients. There was also a significant correlation between sVEGFR-2 and PTX3 but not between VEGF and PTX3.
CONCLUSION: These findings suggest the importance of VEGF, its signal transduction pathways, and the cytokine network and may be useful for understanding the mechanism of macular edema in CRVO and developing new treatments.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23842103     DOI: 10.1097/IAE.0b013e3182993d74

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  7 in total

1.  Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data.

Authors:  Irini Chatziralli; George Theodossiadis; Marilita M Moschos; Panagiotis Mitropoulos; Panagiotis Theodossiadis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-02-18       Impact factor: 3.117

2.  Systemic and Ocular Long Pentraxin 3 in Patients with Age-Related Macular Degeneration.

Authors:  Helene Bæk Juel; Carsten Faber; Lea Munthe-Fog; Simone Bastrup-Birk; Alexander Lynge Reese-Petersen; Mads Krüger Falk; Amardeep Singh; Torben Lykke Sørensen; Peter Garred; Mogens Holst Nissen
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

3.  Increased expression of angiogenic and inflammatory proteins in the vitreous of patients with ischemic central retinal vein occlusion.

Authors:  Christoph Ehlken; Bastian Grundel; Daniel Michels; Bernd Junker; Andreas Stahl; Günther Schlunck; Lutz L Hansen; Nicolas Feltgen; Gottfried Martin; Hansjürgen T Agostini; Amelie Pielen
Journal:  PLoS One       Date:  2015-05-15       Impact factor: 3.240

4.  Elevated plasma pentraxin 3 and its association with retinal vein occlusion.

Authors:  Kyung Soo Park; Ji Wan Kim; Jae Hwan An; Je Moon Woo
Journal:  Korean J Ophthalmol       Date:  2014-11-19

5.  Anti-vascular endothelial growth factor agent reduces inflammation in macular edema with central retinal vein occlusion.

Authors:  Asako Mashima; Hidetaka Noma; Kanako Yasuda; Hiroshi Goto; Masahiko Shimura
Journal:  J Inflamm (Lond)       Date:  2019-05-22       Impact factor: 4.981

Review 6.  A Review of Intraocular Biomolecules in Retinal Vein Occlusion: Toward Potential Biomarkers for Companion Diagnostics.

Authors:  Bingjie Wang; Xiao Zhang; Huan Chen; Adrian Koh; Chan Zhao; Youxin Chen
Journal:  Front Pharmacol       Date:  2022-04-26       Impact factor: 5.988

7.  IL-18 and S100A12 Are Upregulated in Experimental Central Retinal Vein Occlusion.

Authors:  Lasse Jørgensen Cehofski; Anders Kruse; Svend Kirkeby; Alexander Nørgård Alsing; Jonas Ellegaard Nielsen; Kentaro Kojima; Bent Honoré; Henrik Vorum
Journal:  Int J Mol Sci       Date:  2018-10-25       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.